PC25144A Issue Fee for Appln No. 10/754,171



I hereby certify that this correspondence is being deposited with the United States Postal Service Express Mail (EV 723989573) in an envelope addressed to: Mail Stop ISSUE FEE, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, pn this 22th day of July 2005.

Christina M. Compelube

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Suzanne Benedict, et al.

Serial No.: 10/754,171

Filed: January 9, 2004

**Confirmation No.: 8481** 

For: TRICYCLIC COMPOUNDS PROTEIN

KINASE INHIBITORS FOR

**ENHANCING THE EFFICACY OF ANTI-**

NEOPLASTIC AGENTS AND RADIATION THERAPY

Group Art Unit: 1625

**Examiner: Charanjit Aulakh** 

Attorney Docket No.: PC25144A

Mail Stop: ISSUE FEE

Honorable Commissioner For Patents

P.O. Box 1450

Alexandria, VA 22313-1450

#### TRANSMITTAL LETTER

Transmitted herewith are the following documents:

1. Form PTOL-85

2. Return Postcard

3. Comments on Statement of Reason for Allowance

4. Total Fee Due

1 Page + Duplicate;

1 Postcard; and

2 pages

Deposit Account.

Respectfully submitted,

Date: July 22, 2005

Ye Hua

Agent For Applicants Registration No. 53,042

Agouron Pharmaceuticals, Inc./A Pfizer Company Patent Department 10777 Science Center Drive San Diego, California 92121 Phane: (858) 622 3020

Phone: (858) 622.3020 Fax: (858) 678-8233

## Certificate of Mailing (37 C.F.R. §1.10):

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (EV 723989573 US) in an envelope addressed to: Mail Stop AMENDMENT, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 22<sup>th</sup> day of July2005.

s/ Christina M. Compelube

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Benedict, et al.

**Group Art Unit: 1625** 

Serial No.: 10/754,171

Examiner: Aulakh, Charanjit

Confirmation No.: 8481

Filed: January 9, 2004

Attorney Docket No.: PC25144A

For: TRICYCLIC COMPOUNDS PROTEIN

KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY

Mail Stop ISSUE FEE Honorable Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## COMMENTS ON STATEMENT OF REASON FOR ALLOWANCE

Sir:

In response to the Notice of Allowance mailed June 30, 2005, Applicants herein make the following comments on statement of reason for allowance.

Comments begin on page 2 of this paper.

# Comments

The Examiner stated on page 2 of the Notice of Allowance that the reasons for allowance are that "applicants have either canceled or amended claims to overcome enablement, indefiniteness and prior art rejections and therefore, all 35 U.S.C. 112, first and second paragraph was well as under 35 U.S.C. 102(b) are now withdrawn".

Applicants would like to restate that Applicants do not acquiescence to the merits of the 102(b) prior art rejection of claims 1, 2, 18-21, 24, 27-31, and 33-45 made by the Examiner regarding reference Webber (WO 00/42040). Claim 1 was amended to expedite prosecution.

Applicants would like to further state that Applicants do not acquiescence to the merits of enablement and indefiniteness rejection of 35 U.S.C. 112 first paragraph and second paragraph of claims 2, and 33-45. Claims 2 and 33-45 were canceled to expedite prosecution.

If any fees other than those submitted herewith are due in connection with this response, please charge such fees to Deposit Account No. 500329.

Respectfully submitted,

Date: July 22, 2005

Ye Hua

Agent For Applicants Registration No. 53,042

Agouron Pharmaceuticals, Inc./A Pfizer Company Patent Department 10777 Science Center Drive San Diego, California 92121

Phone: (858) 622-3020 Fax: (858) 678-8233